|Articles|June 15, 2004
Topical cyclosporine can handle more than dry-eye disease
Any T-cell-mediated disease benefits from therapy without affecting other inflammatory pathways
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
2
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment
3
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study
4
Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS
5













































.png)


